Literature DB >> 17479201

Effects of hypolipemic drugs on the osteoprotegerin - sRANKL system in patients with coronary artery disease.

Magdalena Celińska-Löwenhoff, Tomasz Löwenhoff, Anetta Undas, Piotr Gluszko.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17479201

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  4 in total

1.  Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis.

Authors:  Constantinos Giaginis; Aikaterini Papadopouli; Athina Zira; Athanasios Katsargyris; Christos Klonaris; Stamatios Theocharis
Journal:  Med Sci Monit       Date:  2012-10

2.  The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats.

Authors:  Astrid K Stunes; Irene Westbroek; Björn I Gustafsson; Reidar Fossmark; Jan H Waarsing; Erik F Eriksen; Christiane Petzold; Janne E Reseland; Unni Syversen
Journal:  BMC Endocr Disord       Date:  2011-05-26       Impact factor: 2.763

3.  Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone.

Authors:  Unni Syversen; Astrid K Stunes; Björn I Gustafsson; Karl J Obrant; Lars Nordsletten; Rolf Berge; Liv Thommesen; Janne E Reseland
Journal:  BMC Endocr Disord       Date:  2009-03-30       Impact factor: 2.763

4.  Randomized Placebo-Controlled Trial Assessing the Effect of 24-Week Fenofibrate Therapy on Circulating Markers of Abdominal Aortic Aneurysm: Outcomes From the FAME -2 Trial.

Authors:  Jenna L Pinchbeck; Joseph V Moxon; Sophie E Rowbotham; Michael Bourke; Sharon Lazzaroni; Susan K Morton; Evan O Matthews; Kerolos Hendy; Rhondda E Jones; Bernie Bourke; Rene Jaeggi; Danella Favot; Frank Quigley; Jason S Jenkins; Christopher M Reid; Ramesh Velu; Jonathan Golledge
Journal:  J Am Heart Assoc       Date:  2018-10-02       Impact factor: 5.501
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.